32 / 36
Del Re M,
et al. Cancer Treat Rev
2017;55:71–82.
Potential increase of
moderate type A or F
ADRs
No increase of type A or F
ADRs
Actual and predicted DDIs between
abiraterone-prednisone and enzalutamide
|
|
32 / 36
32 / 36
Del Re M,
et al. Cancer Treat Rev
2017;55:71–82.
Potential increase of
moderate type A or F
ADRs
No increase of type A or F
ADRs
Actual and predicted DDIs between
abiraterone-prednisone and enzalutamide